The Biden administration has issued additional guidance on qualifying as vaccinated under its Coronavirus mandate for federal employees, as well as clarifying prior guidance on documenting that status.
New questions and answers from the Safer Federal Workforce Task Force for example clarify that the U.S.-based AstraZeneca and Novavax COVID-19 vaccines meet the criteria for an employee who participates in a clinical trial to be considered fully vaccinated.
Previously, the guidance had not specified which vaccines qualified under a standard stating that “clinical trial participants from a U.S. site who are documented to have received the full series of an “active” (not placebo) COVID-19 vaccine candidate, for which vaccine efficacy has been independently confirmed (e.g., by a data and safety monitoring board), can be considered fully vaccinated 2 weeks after they have completed the vaccine series.”
The guidance also states that receipt of a heterologous primary vaccine series qualifies for those who are at least two weeks past receiving “any combination of two doses of an FDA approved or authorized or WHO emergency use listed COVID-19 two-dose series.”
The guidance continues to state, as did prior guidance, that “an employee must provide the required documentation for proof of vaccination. A recent antibody test cannot be used to prove vaccination status.”
Also regarding proof of vaccination, the latest update further clarifies what information must be included if the employee provides documents other than the most common types of record such as a vaccination card. Such documents must include “the type of vaccine administered, date(s) of administration, and the name of the health care professional(s) or clinic site(s) administering the vaccine(s).”
It also repeats previous statements that “employees must certify under penalty of perjury that the documentation they are submitting is true and correct.”